Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Jan 19, 2010

Premium

Complete Genomics recently disclosed that Aaron Solomon joined the firm as as vice president of business development and Mauro Folena joined as vice president of operations last year.

Most recently, Solomon was vice president of business development at Tethys Biosciences. Prior to that, he held positions in sales, marketing, and business development at Incyte, ParAllele, and Affymetrix. He graduated from the University of California, Irvine, with a BS in biological sciences

Mauro Folena most recently led advanced manufacturing at Proteus Biomedical. Before that, he was director of operations at Coherent, vice president of operations at Aerogen, and held positions at Honeywell International and National Semiconductor. Folena holds a BS in information systems management from the University of San Francisco.

Further, Eric Lachenmeier left Complete Genomics last year, and Arnold Oliphant the year before, according to the company. Lachenmeier was vice president of corporate programs and Oliphant executive vice president for scientific operations.


Laurent Alexandre has been appointed as president and chairman of the board of DNA Vision, a genetic analysis service provider based in Brussels, Belgium. He will help the company develop a new business model that is centered on personalized medicine and consumer genomics. Alexandre is a surgeon and urologist and holds an MBA from HEC Paris, as well as degrees from the Paris Institute of Political Studies and from the École Nationale d'Administration.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.